Latest News

Latest News

Weekly News Roundup | 07 September 2026

Weekly News Roundup | 07 September 2026

Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...

read more
Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven

Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven

Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

UK Boosts Clinical Trials With Faster, Agile Regulation

UK Boosts Clinical Trials With Faster, Agile Regulation

Press Release: Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation  The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more...

read more
Five Ways AI Will Reshape Life Sciences in 2026

Five Ways AI Will Reshape Life Sciences in 2026

Why People, Process, and Purpose Matter Most Following a period of experimentation, life sciences is entering a pivotal new phase in AI adoption. The industry is shifting away from hype-driven pilots and toward proven, value-led applications that improve how therapies...

read more
Why Hormone Tracking will be a Key Health Trend for 2026

Why Hormone Tracking will be a Key Health Trend for 2026

Hormone health expert and bestselling author Dr Louise Newson explains why we'll all be tracking our hormones in 2026. The use of period tracking apps and menopause symptom tracker apps are at an all-time high. And it’s no wonder. These apps can be incredibly useful...

read more
OpenAI Accelerates Healthcare Strategy With ChatGPT Health

OpenAI Accelerates Healthcare Strategy With ChatGPT Health

OpenAI is making its most coordinated move into healthcare to date, positioning ChatGPT Health as a central interface for clinical, research, and operational use across the medical ecosystem. Rather than launching a single consumer-facing medical product, the company...

read more
The Lost World of Autism

The Lost World of Autism

Dhruv Shenai explores how females have been left behind in conversations on autism by discussing the history and lack of female representation within the field. Neuroscientist Gina Rippon has spent years challenging the male-centred bias in autism research. Her new...

read more
UK Boosts Clinical Trials With Faster, Agile Regulation

UK Boosts Clinical Trials With Faster, Agile Regulation

Press Release: Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation  The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more...

read more
Five Ways AI Will Reshape Life Sciences in 2026

Five Ways AI Will Reshape Life Sciences in 2026

Why People, Process, and Purpose Matter Most Following a period of experimentation, life sciences is entering a pivotal new phase in AI adoption. The industry is shifting away from hype-driven pilots and toward proven, value-led applications that improve how therapies...

read more
Why Hormone Tracking will be a Key Health Trend for 2026

Why Hormone Tracking will be a Key Health Trend for 2026

Hormone health expert and bestselling author Dr Louise Newson explains why we'll all be tracking our hormones in 2026. The use of period tracking apps and menopause symptom tracker apps are at an all-time high. And it’s no wonder. These apps can be incredibly useful...

read more
OpenAI Accelerates Healthcare Strategy With ChatGPT Health

OpenAI Accelerates Healthcare Strategy With ChatGPT Health

OpenAI is making its most coordinated move into healthcare to date, positioning ChatGPT Health as a central interface for clinical, research, and operational use across the medical ecosystem. Rather than launching a single consumer-facing medical product, the company...

read more
The Lost World of Autism

The Lost World of Autism

Dhruv Shenai explores how females have been left behind in conversations on autism by discussing the history and lack of female representation within the field. Neuroscientist Gina Rippon has spent years challenging the male-centred bias in autism research. Her new...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Why Life Sciences Can no Longer Rely on Traditional Media

Why Life Sciences Can no Longer Rely on Traditional Media

The life sciences industry is advancing at a speed that would have felt unimaginable just a few years ago. Artificial intelligence is shortening drug discovery timelines. Digital therapeutics are reshaping care delivery. Precision medicine is moving healthcare from...

read more
Prostate Cancer Screening: What You Need to Know

Prostate Cancer Screening: What You Need to Know

Prostate cancer is one of the most common cancers affecting men worldwide. Across the UK, Europe and the United States, it remains a leading cause of cancer diagnosis in men and a significant contributor to cancer related mortality. Despite its prevalence, prostate...

read more
Lego for Biotech Labs

Lego for Biotech Labs

How Modular Hardware Is Breaking Decades of Vendor Lock-In There’s a running joke among biotech lab managers that goes something like this: You don’t buy a bioreactor. You buy a relationship. A very expensive, very locked-in relationship. It’s funny because it’s...

read more
J&J Axes Eczema Drug From $1.25B Acquisition

J&J Axes Eczema Drug From $1.25B Acquisition

Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...

read more
7,000 Steps a Day May Improve Brain and Reduce Disease Risk

7,000 Steps a Day May Improve Brain and Reduce Disease Risk

Walking around 7,000 steps each day could help sharpen cognition and shield against a variety of chronic illnesses, according to a major new analysis. This target may be more attainable, yet still effective, than the widely publicised 10,000 step goal. Published in...

read more
The Boom in Life Sciences in India

The Boom in Life Sciences in India

India is emerging as one of the most dynamic life sciences markets in the world. Long recognised for its strength in pharmaceuticals and generics, the country is now experiencing a broader life sciences boom that spans biotechnology, vaccines, medical devices,...

read more
Mapping a Single Neuron

Mapping a Single Neuron

This visualization from the Lichtman Lab and Google Connectomics captures one of the most detailed looks we’ve ever had at a single cortical neuron. What you’re seeing isn’t an artist’s rendering — it’s a true 3D reconstruction built from electron microscopy, stitched...

read more

Further News

Compliant on Paper, Exposed in Practice

A pharmaceutical manufacturer completes a technology transfer. The validation protocols have been approved. Training records are complete, documentation has been reviewed, and every required signature has been collected. The project passes its milestones and moves...

The One Leadership Skill That Turns the Ordinary Into the Extraordinary

As healthcare and life sciences organizations confront workforce shortages, regulatory pressures, rapid technological change, and increasing operational complexity, building a pipeline of extraordinary leaders has never been more important. Many of these organizations...

From Reactive Reviews to Predictive Regulatory Intelligence

Every regulatory professional has experienced the same moment. After months, and sometimes years, of preparing a Chemistry, Manufacturing, and Controls (CMC) submission, the application is finally submitted to a health authority. At that point, the questions begin....

The Patient as Healthcare’s Systems Integrator

Healthcare has undergone a remarkable digital transformation over the past two decades. Electronic health records, electronic prescribing, patient portals, telemedicine, artificial intelligence, and remote monitoring have fundamentally changed how healthcare is...

Why AI in Life Sciences Lives or Dies on its Data Foundations

AI has moved quickly in the life sciences making exciting breakthroughs and reframing how we think about healthcare. But beneath these breakthroughs, work is happening in places that rarely make headlines, data catalogues, validation plans, audit trails, integration...

Healthcare’s Claim-Denial Crisis Is an Administrative Epidemic

Healthcare has a second epidemic running alongside every clinical one, and it doesn't show up on a chart. It shows up in a fax queue. A claim gets denied, and somewhere in a hospital's business office, a trained professional begins a process that looks less like...

Next-Gen 3D Models: A Webinar on Elevating Brain Organoid Fidelity

Human brain organoids have fundamentally shifted the paradigm of neurological research. By transforming human pluripotent stem cells (hPSCs) into self-organizing, three-dimensional tissues, these models provide an unprecedented window into the distinct spatial...

Weekly News Roundup | 20 July 2026

Life science news 20 July 2026: the FDA approves the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly makes the largest psychedelics deal in Big Pharma history, and a first-in-class breast cancer therapy wins regulatory clearance in a landmark week for...

The NewCo Model: How Big Pharma Spins Out Pipeline Assets

The NewCo model biopharma strategy has rapidly become one of the most consequential dealmaking trends in the life sciences industry. Rather than shelving deprioritised pipeline assets or selling them outright through traditional licensing agreements, major...

Diranersen: First Tau Drug to Show Cognitive Benefit in Alzheimer’s

The first Phase 2 clinical evidence that a tau Alzheimer's drug can simultaneously reduce brain tangles and slow cognitive decline was presented at the Alzheimer's Association International Conference (AAIC) 2026 in London on 14 July. Biogen's diranersen, an antisense...

NAMs and Animal Testing: Separating Progress From Hype

If you followed the headlines over the past two years, you could be forgiven for thinking animal testing in drug development is already on its way out. In December 2022, the FDA Modernization Act 2.0 removed the blanket legal requirement for animal studies to support...

Clinical Trials Roundup | 17 July 2026

Celcuity's gedatolisib receives FDA approval as the first pan-PI3K and mTOR inhibitor for advanced breast cancer, Biogen's diranersen delivers detailed Phase 2 CELIA data showing tau reduction and cognitive benefit in early Alzheimer's disease, Novo Nordisk's...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.